

SUPPLEMENTAL MATERIAL

Supplemental Table

Table S1. Characteristics of groups with incomplete vs. complete 6-minute walk test distance data

Values are shown as absolute numbers (percentages and mean \pm SD or median with IQR). AF indicates atrial fibrillation; BMI, body mass index; eGFR, estimated glomerular filtration rate; IQR, interquartile range; KCCQ-OS, Kansas City Cardiomyopathy Questionnaire overall summary score; NTproBNP, N-terminal pro B-type natriuretic peptide; NYHA, New York Heart Association; SD, standard deviation; and 6MWT, 6-minute walk test.

Characteristics	Incomplete vs Complete Data		Total	P-Value
	Incomplete n = 35	Complete n = 289	n = 324	
Female, n (%)	21 (60.0)	163 (56.4)	184 (56.8)	0.684
Age, y	71.9 \pm 8.2	69.4 \pm 10.6	69.6 \pm 10.4	0.172
White, n (%)	21 (61.8)	196 (68.8%)	217 (68.0)	0.407
Dapagliflozin treatment group	16 (45.7)	146 (50.5)	162 (50.0)	0.591
Type 2 diabetes, n (%)	20 (57.1)	161 (55.7)	181 (55.9)	0.871
AF, n (%)				
No AF	14 (40.0)	139 (48.1)	153 (47.2)	
Paroxysmal AF	11 (31.4)	78 (27.0)	89 (27.5)	
Persistent AF	10 (28.6)	72 (24.9)	82 (25.3)	0.662
Ejection fraction (%)	59.7 \pm 8.2	59.4 \pm 7.7	59.4 \pm 7.8	0.849
eGFR, mL/min/1.73 meter squared	49.0 \pm 18.5	58.2 \pm 20.9	57.2 \pm 20.8	0.012
BMI, kg/m ²				
Mean \pm SD	33.3 \pm 7.8	36.0 \pm 8.4	35.7 \pm 8.4	
Median (IQR)	33.1 (27.8, 36.8)	34.8 (30.5, 41.4)	34.8 (30.2, 41.0)	0.083
6MWT distance, m (baseline)	200.0 \pm 111.6	249.0 \pm 113.8	244.4 \pm 114.4	
Missing	5	0	5	0.025
6MWT distance, m (week-12)	142.1 \pm 20.4	252.1 \pm 119.3	251.4 \pm 119.3	
Missing	33	0	33	0.194
Loop diuretic dose > 40 mg/day, n (%)	18 (51.4)	93 (32.2)	111 (34.3)	0.023
NYHA Class III, n (%)	25 (71.4)	112 (38.8)	137 (42.3)	< 0.001
NT-proBNP (pg/mL)				
Mean \pm SD	1405.5 \pm 1180.4	1088.3 \pm 1508.2	1122.6 \pm 1478.0	
Median (IQR)	1224.0 (543.0, 2073.0)	648.0 (352.0, 1195.0)	671.0 (356.0, 1309.0)	0.231
KCCQ-OS				
Mean \pm SD	56.7 \pm 18.3	63.4 \pm 20.6	62.7 \pm 20.4	
Median (IQR)	59.7 (43.0, 68.8)	64.8 (49.0, 79.4)	63.8 (48.4, 78.1)	0.065

Supplemental Figure

Figure S1. Responder analysis (using 20 m) of effects of dapagliflozin (Dapa) on 6-minute walk test (6MWT) distance.

A, Data are represented as proportion of patients experiencing 6MWT distance deterioration, no change, or improvement per treatment group. **B**, Likelihood of improvement ≥ 20 m vs deterioration ≤ 20 m on Dapa (vs placebo) after adjusting for baseline measurements including age, sex, race, history of diabetes, body mass index (BMI), left ventricular ejection fraction (LVEF), history, and type of atrial fibrillation (AF), Kansas City Cardiomyopathy Questionnaire (KCCQ), estimated glomerular filtration rate (eGFR), loop diuretic dose, New York Heart Association (NYHA) functional class, N-terminal pro B-type natriuretic peptide (NT-proBNP) and baseline 6MWT distance.

